Electronic Trial Master File (eTMF) Systems Market - Industry-Specific Opportunities and Trends Affecting the Growth
2022-06-08 11:26:01 UTC | Healthcare & Pharmaceuticals
MarketsandMarkets™ Research Report's View on Revenue Impact?
The electronic trial master file (eTMF) systems market is projected to reach USD 1.8 billion by 2024 from USD 1.0 billion in 2019, at a CAGR of 12.7%.
Factors Responsible for Growth and In-Depth Analysis?
The Growth in the eTMF systems market can be attributed primarily to the rising adoption of eTMF systems, rising number of clinical trials, partnerships between biopharma companies & CROs, increasing funding to support clinical trials, and the growth in the R&D spending by pharma & biotech companies. Emerging countries are expected to provide significant opportunities for players in the market. However, budget constraints, data privacy issues, and a dearth of skilled professionals will challenge market growth in the coming years
Leading Key Players and Analysis:
Veeva Systems (US), Oracle Corporation (US), Phlexglobal Limited (UK), TransPerfect Global Inc. (US), Aurea Software (US), LabCorp (US), ePharmaSolutions (US), Wingspan Technology, Inc. (US), MasterControl (US), SureClinical, Inc. (US), Dell EMC (US), Paragon Solutions (US), PharmaVigilant (US), Mayo Clinic (US), Database Integrations, Inc. (US), CareLex (US), Ennov (France), Forte Research (US), Freyr (US), Montrium (US), NCGS Inc. (US), SAFE-BioPharma (US), SterlingBio Inc. (US), BIOVIA Corp. (US), and arivis AG (Germany) are the key players in the eTMF systems market
Geographical Analysis in Detailed?
North America accounted for the largest share of the market in 2018. The large market share of North America in the market can be attributed to the increasing government funding for clinical research, a large number of clinical trials, and the presence of several major players in the US.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=94357456
The availability of substantial R&D budgets with large pharmaceutical & biotechnology companies will drive the adoption of the eTMF systems among pharmaceutical & biotechnology companies.
Based on end-user, the eTMF systems market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and other end-users (medical device companies, academic research institutes, and consulting service companies). The pharmaceutical & biotechnology companies segment accounted for the largest market share in 2018. The increasing applications of eTMF software in clinical project management and the availability of substantial R&D budgets with large pharmaceutical & biotechnology companies will drive the adoption of eTMF systems in this end-user segment.
The heavy dependence of end-users on service providers will drive the services segment in the eTMF systems market
Based on the component, the market is segmented into services and software. The services segment accounted for the largest market share in 2018. The large share of this segment can be attributed to their indispensable nature and repetitive requirement. End-users of eTMF systems rely heavily on service providers for consulting, data storage, implementing services, training, maintenance, and regular upgrades of solutions.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=94357456